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Metastatic and local advanced unresectable pancreatic cancers are lethal con-
ditions that always carry a poor prognosis with rare exceptions. Currently, the 
mainstay of therapy is cytotoxic chemotherapy plus best supportive care. First-line 
therapy for patients with a good performance status includes FOLFIRINOX or 
gemcitabine plus nab-paclitaxel regimens. Patients carrying a deleterious germline 
BRCA mutation can be treated with maintenance olaparib after FOLFIRINOX. 
Patients with a poor performance status, but still fit enough for chemotherapy, 
may be treated with single agent gemcitabine. Second-line therapy will depend 
on previous therapy and current performance status. Options for patients treated 
with gemcitabine-based regimens are 5-fluorouracil plus leucovorin plus either 
nanoliposomal irinotecan, irinotecan or oxaliplatin. Patients that were treated with 
first line FOLFIRINOX may benefit from a gemcitabine-based chemotherapy, but 
evidence from randomized trials is lacking. Other options like immunotherapy and 
targeted therapies yield benefit only in very selected cases, and it is still an area of 
research.
Keywords: metastatic pancreatic cancer, unresectable pancreatic cancer, 
local advanced pancreatic cancer, FOLFIRINOX, nab-paclitaxel, gemcitabine, 
nanoliposomal irinotecan, olaparib, BRCA pancreatic cancer
1. Introduction
Advanced exocrine pancreatic cancer (PC) is one of the most lethal malignan-
cies among all types of solid tumors. According to data from United States of 
America (USA) registries, 29% of the patients will debut with locally advanced 
disease, and 53% will have metastases at diagnosis [1]. Even in the cases when 
resection is feasible, long-term survival rates are among 3.9 and 9.3%, meanwhile 
5 years-overall survival for stage IV is lesser than 3% [1, 2]. The late stage at 
presentation and the particular microenvironment characterized by predominant 
desmoplastic tissue and immunosuppressive cells explain why PC poses such a 
challenge [3].
Historically, median overall survival (mOS) for advanced stages was around 
6 months when the patient was treated with gemcitabine or gemcitabine-based 
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combinations but new chemotherapy regimens and better understanding of the 
tumor biology has led to improved, yet still poor, survival [4].
Unlike other cancers, target therapy has yielded only modest benefit in PC. 
There are only two targeted agents than historically have got approval for metastatic 
or unresectable PC: erlotinib and olaparib. Erlotinib, a tyrosine kinase inhibitor 
(TKi) targeting the epidermal grow factor receptor (EGFR), in combination with 
gemcitabine, when compared with gemcitabine alone, showed a statistically signifi-
cant, but clinically modest benefit in OS [5]. Just recently, the US Food and Drug 
Administration (FDA) approved the PARP inhibitor olaparib for PC in patients 
with deleterious or suspected deleterious germline BRCA mutations [6], which are 
present only in approximately 5% of pancreatic cancer patients.
Immunotherapy has showed great advances in melanoma and lung cancer 
among others, has not yield any promising results in PC. The site agnostic FDA 
approval for checkpoint inhibitors for mismatch repair deficient tumors (dMMR) 
or tumors with high microsatellite instability (MSI-H) has modest impact in PC [7], 
given that those abnormalities are infrequent in pancreatic adenocarcinoma.
Current research is looking for development of new drugs with different mecha-
nisms of action in order to overcome chemotherapy resistance wishing to improve 
survival and quality of life in advanced PC patients.
Considering that pancreatic cancer is mainly a systemic disease we have focused 
this chapter in systemic treatments addressed to unrecoverable patients and we will 
not refer here to local treatments such as radiation therapy or chemoradiation that 
can be curative in a very small amount of patients but that do not have a real impact 
in survival in the metastatic or micrometastatic scenario.
2.  First steps: chemotherapy development in metastatic or unresectable 
pancreatic adenocarcinoma
Earlier tested in gastric cancer by the Southwest Oncology Group the combina-
tion of 5-Fluoruracil, Adriamycin and Mitomycin C (FAM) was later assessed 
in advanced PC patients and published in 1980. Smith et al. reported a 37% of 
partial responses (PR) and 11% of stable disease (SD) among 27 patients that were 
treated with this regimen and had measurable disease, with a median duration 
of response (mDOR) of 9 months. Patients with better performance status were 
more likely to response (55%) and patients with Performance Status (PS)2–3 
only achieved a 29% of response rate (RR) (p < 0.15). Median OS was higher 
in patients that responded (12 months) when compared with nonresponders 
(3.5 months) (p < 0.01). Myelosuppression was the most relevant toxicity 
reported in this trial [8].
In 1985, a multicenter phase 3 clinical trial that compared 5-Fluoruracil 
(5FU) alone or in combination with Adriamycin (FA) or in combination with 
Adriamycin plus Mitomycin C (FAM) in treating advanced pancreatic and gastric 
carcinoma was published. This trial that included 144 PC patients from 11 centers 
of the United States with advanced or metastatic adenocarcinoma of the pan-
creas, did not show any benefit of both combination arms when compared with 
5-FU alone in terms of median OS, median time to progression (TTP), objective 
response rate (ORR) and parameters of palliation, however, the reported hema-
tological and nonhematological toxicities were higher in the FA and FAM arms 
when compared with 5 FU alone [9]. This clinical trial led to a decreasing use of 
FAM regimen and for the increasing need to look for new treatments for these 
population of patients.
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3. Gemcitabine: a new era for pancreatic cancer
One decade later, gemcitabine, a nucleoside analogue that exhibits antitumor 
activity, started to show promising results in PC patients.
Conducted as a phase 2 trial by former concepts, Casper et al. reported their 
experience of treating 44 PC patients, all of them with confirmed adenocarcinoma, 
not amenable to curative surgical treatment, performance status 0–1, and measur-
able disease (32 patients with metastatic disease and 12 patients with local advanced 
PC). The initial dose of gemcitabine was 800 mg/m2 weekly for 3 weeks and 1 week 
off. Thirty-five patients received two or more cycles of Gemcitabine. Median TTP 
was 16 weeks. Five patients (11%) achieved a major response according to the radio-
logical criteria used in the trial, the median duration of response for those patients 
was 13 months but only 5.6 months for all the treated population. Reported one-
year survival was 23%. Most of the patients presented mild toxicity to gemcitabine 
including hematological, cutaneous toxicity, alopecia, nausea, vomiting and 
diarrhea. Some of these patients were treated with increasing doses of Gemcitabine, 
1000 mg/m2 then 1250 mg/m2 and 2 patients up to 1500 mg/m2; however, those last 
patients needed a reduction of their doses due to flu-like syndrome [4].
In a phase 3 randomized clinical trial Gemcitabine was compared head to head 
with 5 FU. This study included 126 patients from Canada and the United States 
with locally-advanced-unresectable or metastatic PC. Despite the known limited 
benefit of 5-FU in PC the investigators that designed the trial decided to use it 
as control arm instead of a placebo arm. The primary end point for this trial was 
“Clinical Benefit” (considering analgesic consumption, pain intensity, performance 
status and weight); secondary end points included response rate, time to disease 
progression and survival. Gemcitabine was given as a 1000 mg/m2 intravenous 
regimen weekly for 7 weeks and 1 week of rest, followed by 1000 mg/m2 weekly 
during 3 weeks with 1 week of rest during the rest of the treatment. 5-FU was given 
weekly in a fixed dose of 600 mg/m2 intravenously. Primary end point was met, and 
this resulted in a positive trial achieving a clinical benefit of 23.8% in the gem-
citabine arm and only 4.8% in the 5 FU arm. Median OS and TTP were 5.6 months 
and 9 weeks for gemcitabine arm versus 4.4 months and 4 weeks for 5FU arm, 
reported 12-months survival was 18 and 2% for gemcitabine and 5FU respectively 
(p = 0.0025). Among gemcitabine treated patients only a 5.4% achieved a radio-
logical response but none from the 5 FU arm did, 39 and 19% of SD was reported 
for both arms. When compared responders versus nonresponder median OS was 
10.7 months versus 4.8 months regardless of the treatment arm. Grade 3–4 neutro-
penia was higher in the gemcitabine arm (25.9% versus 4.9% for 5-FU, p < 0.001), 
No severe infections were reported in either arms but grade 3 and 4 anemia was 
9.7% in gemcitabine arm and 0% in 5 FU arm, grade 1–2 fever was higher in gem-
citabine arm 30.1% versus 16% for 5-FU, rashes 23.8 versus 12.9%, grade 3–4 nausea 
vomiting 9.5 and 3.2% versus 4.8 and 0% respectively. For both arms there were 
no survivors after 19 months since starting treatment [10]. This trial led to FDA 
to approve Gemcitabine as a first line of treatment for unresectable or metastatic 
pancreatic cancer in 1996.
Due to the positive results of gemcitabine in patients with advanced PC many 
combinations of gemcitabine-based treatments were tested looking to improve OS 
and progression free survival (PFS), most of them did not show improvement in 
overall survival as shown in HU’s meta-analysis [11]: gemcitabine—5-FU combi-
nation (conducted by J. D. Berlin); gemcitabine—irinotecan combination (trials 
conducted by G. Rocha Lima and by G.P. Stathopoulos); gemcitabine—oxaliplatin 
(trials conducted by C. Louvet and by E. Poplin); gemcitabine—pemetrexed 
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(conducted by H Oettle); gemcitabine—exatecan (conducted by G. Abou-Alfa); 
gemcitabine—cisplatin (trials conducted by V. Heinemann and by G. Colucci); 
gemcitabine—capecitabine (conducted by D. Cunningham); gemcitabine—beva-
cizumab (conducted by H. Kindler); gemcitabine—cetuximab (conducted by P. 
Philip); gemcitabine—axitinib (conducted by H. Kindler). Gemcitabine—sorafenib 
combination also resulted in negative trials in terms of overall survival [12].
Despite those several negative clinical trials, a meta-analysis conducted by Ciliberto 
aimed to evaluate the role of gemcitabine-based combination therapy when compared 
with gemcitabine alone. Including more than 10.600 patients from 34 randomized 
trials, the combination treatments showed marginal superiority in terms of survival, 
overall response, and disease control rate but with higher toxicity rates mainly diar-
rhea, nausea, neutropenia, thrombocytopenia. One of the interpretations of the 
authors was that combination regimens gemcitabine-based should be reserved only for 
well selected patient populations [13]. In an Asiatic population study, a 3-arms clinical 
trial was conducted to compare gemcitabine alone, gemcitabine plus S-1 combination 
or S-1 alone in local advanced and in metastatic pancreatic patients. The combination 
arm did not show superiority when compared with gemcitabine alone, however, S-1 
showed noninferiority against gemcitabine with a good tolerability profile [14].
From PC biopsies Fjallskog et al. found and reported that 55% of tumor samples 
studied stained positive for Epidermal Growth Factor Receptor (EGFR) [15]. In 
a murine model of pancreatic adenocarcinoma adding erlotinib highly inhibited 
gemcitabine-induced MAP kinase signaling regardless of the activation of KRAS 
by maintaining high levels of ERBB2 protein [16]. A multicenter phase 3 double 
blind international trial assessed gemcitabine plus erlotinib combination versus 
gemcitabine plus placebo [5]. About 569 patients with unresectable or metastatic 
adenocarcinoma of the pancreas, ECOG 0–2 were randomized in a 1:1 ratio to 
receive either gemcitabine alone or gemcitabine plus erlotinib. Gemcitabine was 
given intravenously 1000 mg/m2 weekly for 7 weeks and 1 week off, then 1000 mg/
m2 weekly for 3 weeks and 1 week off during the next cycles (28 days cycle). 
Erlotinib was orally given in a 100 mg dose and increased to 150 mg in a Canadian 
cohort. The primary end point was OS, secondary end points included PFS, ORR, 
duration of response, correlation of EGFR expression with outcomes, quality of life 
and toxicity. Reported median survival and one-year survival were 6.24 months 
and 23% for the gemcitabine—erlotinib arm versus 5.9 months and 17% for the 
gemcitabine-placebo arm. PFS was improved in the combination arm. Despite these 
positive results in statistical terms, the clinical value was marginal and the reported 
toxicity significantly higher in the combination arm, including 6 deaths protocol-
related all of them in patients in the gemcitabine-erlotinib arm including interstitial 
pneumonitis, sepsis, stroke and neutropenic sepsis. Immunohistochemical analysis 
and correlation with response did not show any improvement among EGFR positive 
patients. Interestingly, patients that developed skin rash grade 2 or higher lived lon-
ger when compared with whom did not (10.5 months for grade 2 versus 5.8 months 
and 5.3 months for grade 1 and 0 respectively), 1-year survival was 16% for rash 
grade, 0, 9% for rash grade 1 and 43% for rash grade 2 or higher (p < 0.001).
A German trial that compared erlotinib in combination with either capecitabine 
or gemcitabine as the front-line treatment for advanced pancreatic cancer patients 
allowing cross over after failure showed a low toxicity rate for both arms and not 
deaths treatment-related [17].
Despite that gemcitabine-erlotinib combination got FDA approval for metastatic 
or unresectable PC, considering its minimal benefit in terms of survival when com-
pared with gemcitabine alone and also due to the higher toxicity profile of the com-
bination, it is not considered as a “first option of treatment” in advanced pancreatic 
adenocarcinoma patient by different authors and international guidelines [18, 19].
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4.  2020: current first-line options for the treatment of metastatic and 
or unresectable adenocarcinoma of the pancreas and their historical 
development
Based on the knowledge from preclinical assays and clinical studies that had 
showed synergist activity of irinotecan, oxaliplatin and 5-FU combination, a phase 
1 trial assessed a regimen that combined 5-FU, leucovorin. Irinotecan and oxalipla-
tin [20]. This trial included 34 patients with different malignancies, 6 of them with 
pancreatic advanced cancer. Among pancreatic cancer patients one partial response 
and one complete response were achieved. For all the patients treated main grade 
3–4 toxicities included 78% neutropenia (12% febrile neutropenia), 41% asthenia, 
37% peripheral neuropathy, 27% diarrhea and 24% nausea and vomiting, 6% 
thrombocytopenia and 5% anemia. 51% of the patients required granulocyte colony 
stimulating factor (G-CSF).
FOLFIRINOX regimen (oxaliplatin 85 mg/m2 + Irinotecan 180 mg/
m2 + Leucovorin 400 mg/m2 + 5-FU 400 mg/m2 in bolus and 5-FU 2400 mg/m2 in 
46 hours in continuous infusion) every 2 weeks was evaluated in a phase 2 French 
clinical trial that included 46 patients with advanced or metastatic pancreatic 
adenocarcinoma that had not received previous treatment (chemotherapy, radio-
therapy or chemoradiation), with ages between 18 and 70 years, performance status 
0–1, adequate bone marrow function, total bilirubin not superior than 1.5 times the 
upper normal level (UNL), AST – ALT and alkaline phosphatases <3 ULN (5 < ULN 
in patients with liver metastasis) and an adequate renal function were some of the 
selection criteria [21]. Patients with brain or leptomeningeal disease were excluded. 
Primary end point of the trial was response rate end according to former WHO 
criteria; secondary end points included safety, quality of life and clinical benefit 
assessment. Treatment was given until progression of disease or unacceptable toxic-
ity for up to 6 months of chemotherapy in case of benefit. According to protocol 
atropine was allowed to be administered to diminish the risk of severe cholinergic 
syndrome in patients that presented it in a previous cycle. Antiemetic prophylaxis 
treatment was permitted at investigator’s discretion. Loperamide was allowed for 
patients with delayed diarrhea and oral fluroquinolones in case that diarrhea lasted 
more than 2 days. After cycle 1 of treatment G-CSFs were also allowed to be used in 
case of need. The median of age of patients was 56 years, 65% were male and 76% 
stage IV B, doses reductions were indicated in the 14% of the total of cycles for all 
the patients. Most of delays for new cycles were due to hematological toxicities. By 
investigators assessment and after a median follow up of 33 months, the overall 
response rate was 26% (all partial responses) and 39% of patients achieved stable 
disease, the median duration of response was 10.4 months, PFS was 5.6 months, 
median OS was 10.2 months (9.5 months for metastatic patients and 15.7 months 
for locally advanced disease), 1-year survival was 43%. Grade 3–4 neutropenia 
occurred in the 52% of patients but only 4% of febrile neutropenia was reported, 
8% of treated patients need hospitalization due to diarrhea, grade 3 and 4 vomiting 
was 20 and 17%, grade 3 and 4 asthenia was 20 and 21%, grade 2 and 3 peripheral 
neuropathy was 13 and 15% respectively and 7 patients were discontinued of 
treatment for this last toxicity. Concerning quality of life 18% of patients reported 
worsening and 37% reported improvement in quality of life.
By those days, the standard of care for advanced PC gemcitabine was compared 
head to head against FOLFIRINOX regimen in a first line of treatment, multicenter 
phase 2–3 clinical trial designed by the same French group [22]. About 342 patients 
were randomized in a 1:1 ratio to receive either FOLFIRINOX every 2 weeks at the 
same doses than in the phase 2 trial or gemcitabine that was given intravenously 
1000 mg/m2 weekly during 7 weeks and 1 week off, then 1000 mg/m2 weekly 
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during 3 weeks and 1 week of rest. Main inclusion criteria were age 18 years or 
older, histologically or cytologically confirmed adenocarcinoma of the pancreas, 
measurable disease, ECOG 0–1 and adequate hepatic, renal and bone marrow func-
tion. Exclusion criteria included but were not limited to an age older than 76 years, 
previous radiotherapy for measurable lesions, brain metastases and others.
OS was the primary end point of this trial. Secondary end points included 
PFS, tumor response, safety and quality of life. The median number of cycles 
was 10 for FOLFIRINOX arm (range 1–47) and 6 for Gemcitabine (range 1–26) 
(p < 0.001). With a median follow up of 26 months median OS was 11.1 months 
for FOLFIRINOX arm and 6.8 months for Gemcitabine arm (HR 0.57; p < 0.001). 
Reported survival rates at 6–12-18 months were 57.6–20.6% and 6% for gemcitabine 
arm and 75.9, 48.4, 18.6% for FOLFIRINOX arm. According to RECIST criteria 
there was a 31.6% of responses among the FOLFIRINOX treated patients includ-
ing 1 complete response but also 38.6% of stable disease as the best response. For 
the gemcitabine arm it was reported a 41.5% of stable disease and only a 9.4% of 
partial responses. Median PFS was 6.4 months and 3.3 months for FOLFIRINOX 
and Gemcitabine arms respectively (HR 0.47; p < 0.001). Patients that received 
a second line of therapy had a median OS de 4.4 months in each group since new 
treatment started. Grade 3 and 4 toxicities were more frequent in the FOLFIRINOX 
arm including neutropenia, febrile neutropenia, thrombocytopenia, diarrhea, 
peripheral neuropathy and also grade 2 alopecia. ALT elevations were significatively 
higher among gemcitabine treated patients. 42% of the FOLFIRINOX-treated 
patients required G-CSF but only 5% of the patients of the gemcitabine arm. At a 
6 months period 66% of gemcitabine treated patients and 31% in the FOLFIRINOX 
arm had a decrease in the scores of quality of life (HR 0.47; p < 0.01). Later reports 
from the same group remarked about the risk of worsening in quality of life among 
patients treated with FOLFIRINOX regimen when compared with gemcitabine-
treated patients [23].
Based on the results of this French trial, FOLFIRINOX has shown to be superior 
in terms of OS, PFS and ORR, and it is currently worldwide accepted as a first line 
option of treatment for patients with advanced PC, however, it is necessary to 
remember that this regimen was approved in patients younger of 76 years old and it 
was assessed only in French population.
Some authors have reported their experiences in patients using some modi-
fications of the FOLFIRINOX regimen (known as modified FOLFIRINOX or 
mFOLFIRINOX). Considering a significant dispersion of results among them, some 
retrospective analysis and meta- analysis showed similar results in terms of sur-
vival but with less toxicity when compared with the results from the pivotal study 
mentioned above [24]. Avoiding 5-FU bolus and using hematopoietic growth fac-
tors also seems to be safe in mFOLFIRINOX regimen when it is used in metastatic 
pancreatic cancer [25].
Before FOLFIRINOX was recognized as the first option of treatment for 
advanced disease the standard of treatment was gemcitabine. Gemcitabine has 
lower efficacy but a better toxicity profile when compared with FOLFIRINOX and it 
can still be used in the first line of treatment among patients that are not amenable 
to receive FOLFIRINOX or gemcitabine-nab paclitaxel combination. Nab-paclitaxel 
is a derivate, solvent-free, albumin bound form of paclitaxel with some relevant 
advantages over paclitaxel including a significant lower hypersensitivity reac-
tions profile and a shorter infusion time. Its formulation with albumin also allows 
nab-paclitaxel to reach the tumor microenvironment by using endogenous albumin 
transport pathways [26]. A glycoprotein that has been related in the carcinogenesis 
of several solid tumors, SPARC (secreted protein acidic and rich in cysteine), 
has been found in high levels in the tumor stroma of pancreatic cancer, mainly in 
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peritumoral fibroblasts and it has been linked with bad prognosis. In complete 
resected patients 5-year survival has been reported to be worse among pancreatic 
cancer patients that express stromal SPARC and it might be considered as a prog-
nostic marker [27]. Tumor stroma’s SPARC seems to facilitate that nab-paclitaxel 
penetrates the tumor microenvironment hypothesizing that this drug may have a 
significant potential role in the pancreatic cancer control [28].
As earlier mentioned in this chapter, gemcitabine was combined with several 
other drugs looking to improve survival and quality of life in advanced PC, unfortu-
nately those trials` outcomes were mostly negative. One exception was gemcitabine 
plus Nab-paclitaxel combination that is currently another recommended first-line 
treatment option in the metastatic setting of patients harboring adenocarcinoma 
of the pancreas. Comparing nab-paclitaxel with other chemotherapy agents, there 
is evidence of synergism in a mouse model when gemcitabine was combined with 
nab-paclitaxel by reducing cytidine deaminase levels that involves gemcitabine’s 
metabolism [29].
A phase 1–2 clinical trial was conducted to define the maximum tolerated dose 
(MTD) of gemcitabine plus Nab-paclitaxel combination in previously untreated 
metastatic PC patients. The regimen was then finally defined as gemcitabine 
1000 mg/m2 plus nab paclitaxel 125 mg/m2 weekly for 3 weeks every 28 days. 
Reported dose limiting toxicities were mainly neutropenia and sepsis. Outcomes 
from patients treated with the MTD showed a 1-year survival of 48%, with a 
median OS of 12.2 months and a response rate of 48%. Interestingly, as part of 
this trial FDG PET CT response was also assessed and showed that patients with 
complete metabolic response had a longer overall survival of 20.1 months ver-
sus 10.3 months in patients that did not achieve a metabolic complete response 
(p = 0.01) [30].
Von Hoff et al., following the previous phase 1–2 trial, designed an interna-
tional multicenter open label phase 3 clinical trial to compare gemcitabine plus 
nab-paclitaxel combination with gemcitabine alone in patients with advanced PC 
(MPACT trial) [31]. The study arm used the same doses of gemcitabine and nab-
paclitaxel suggested by the previous phase1–2 trial. The control arm, gemcitabine 
alone was given in a dose of 1000 mg/m2 weekly for 7 weeks in an 8 weeks cycle 
(defines as protocol as cycle 1) and then 1000 mg/m2 weekly for 3 weeks every 
4 weeks. The primary end point was OS and secondary end points included PFS 
and ORR. Inclusion criteria included patients with a confirmed metastatic adeno-
carcinoma of the pancreas with measurable disease by RECIST 1.0, Karnofsky 
score of 70–100, chemotherapy naive (patients that received previous gemcitabine 
or 5-FU as radiosensitizers were allowed to participate in the trial), adequate 
renal, bone marrow and liver function as defined by protocol. Patients that had 
received adjuvant chemotherapy and patients with locally advance disease were 
excluded. Stratification was according to Karfnofsky score, presence or not of liver 
metastases and geographical region. Randomization was performed in a 1:1 ratio 
and the trial included 861 patients (63% from North America, 15% from Eastern 
Europe, 14% from Australia and 9% from western Europe). 10% of patients were 
older than 75 years and 8% of patients had ECOG 2. The primary end point of the 
trial was met, median OS was 8.5 months for the combination arm and 6>7 months 
for the gemcitabine alone group (HR 0.72; p < 0.001). 1 and 2-year survival were 
higher for the gemcitabine plus nab-paclitaxel combination arm (35 and 9%) arm 
when compared with gemcitabine alone (9 and 4%). Patients that underwent a 
second line of treatment lived longer if they had been treated with the combination 
 treatment (9.4 months for gemcitabine-nab paclitaxel versus 6.8 months for gem-
citabine alone, HR 0.68; p < 0.001). PFS, ORR and disease control rate (DCR)  
were also higher in the combination arm: PFS 5.5 months versus 3.7 months  
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(HR 0.69, p < 0.001), ORR 23% versus 7% (p < 0.001) and DCR of-16 weeks-or-
longer 48% versus 33% respectively (p < 0.001). In addition, patients that had a 
decrease in basal CA 19–9 of 90% or more irrespective of the treatment arm live 
longer when compared with patients that reached a decrease of this biomarker lower 
than 90% (13.5 months versus 8.2 months, HR 0.53; p < 0.001). 15% of patients 
from gemcitabine arm and 32% of the combination arm received at least 6 months 
of treatment. Reported grade 3–4 toxicities were higher among gemcitabine-nab 
paclitaxel arm (neutropenia 38 vs. 27%, leukopenia 31 vs. 16%, fatigue 17 vs. 7%, 
peripheral neuropathy 17 vs. 1%, diarrhea 6 vs. 1%). Discontinuation of nab pacli-
taxel due to peripheral neuropathy grade 1–3 was 8% and no grade 4 neuropathy was 
reported. 3% of patients in the combination arm developed febrile neutropenia and 
26% receipted G-CSF versus 1 and 15% for gemcitabine arm respectively. There was 
a 4% of fatal events in each group but sepsis and pneumonitis related deaths were 
more frequent among gemcitabine plus nab paclitaxel treated patients.
Un update of the long-term survival of this trial was later published [32]. The 
median OS for the gemcitabine-nab paclitaxel combination was 8.7 months versus 
6.6 months for the gemcitabine arm (HR 0.72; p < 0.001). Patients that lived 3 years 
or longer was only a 4% and they all had been treated with the combination treat-
ment. Higher CA 19–9 and neutrophil to lymphocyte ratio > 5 were associated 
with worse survival and there was a trend for more benefit in those poor prognosis 
subgroups.
The phase 2 multicenter, international, single arm LAPACT trial was addressed 
to assess the efficacy and safety of gemcitabine plus Nab-paclitaxel combination in 
patients with locally advanced, unresectable nonmetastatic, previously untreated 
pancreatic cancer [33]. Primary end point was time to treatment failure (TTF). 
This study was designed for all the patients to be treated in a “induction phase” 
with gemcitabine 1000 mg/m2 plus nab-paclitaxel 125 mg/m2 weekly for 3 weeks in 
a 28 days cycle for a total of 6 cycles. After this induction period, patients without 
disease progression, by investigator choice, were treated with the same chemo-
therapy regimen or chemoradiation or surgery (patients with responses before this 
6 cycles period could undergo surgery without have to end the complete all pre-
programmed chemotherapy treatment). Only ECOG 0–1 patients were allowed to 
be enrolled. A total of 106 patients were evaluable. Median TTF was 8.6 months and 
PFS 10.2 months. Main reasons for discontinuing treatment were adverse events 
(18%) and progressive disease (7%). Grade 3 or higher toxicity reported included 
42% neutropenia, 11% anemia, 10% fatigue and 4% of peripheral neuropathy. 
Respecting to efficacy to treatment 32.7% of patients had a partial response and 
57.9% stable disease as the best reported response. 43% of patients continue treat-
ment with gemcitabine plus nab paclitaxel after induction treatment, 16% under-
went chemoradiation and 15% of patients underwent surgery (n 16). Of the 16 
patients that underwent surgery, 7 patients achieved a R0 resection and 9 patients a 
R1 resection.
This chemotherapy regimen, gemcitabine plus nab-paclitaxel combination, is 
currently also an option to consider for unresectable patients, with a very low cura-
tive option, in tumors that have a real minor chance to undergo a R0 resection, as it 
has already been already described for FOLFIRINOX and chemoradiation [34, 35].
No phase 3 clinical trial has compared the efficacy of FOLFIRINOX and gem-
citabine plus nab-paclitaxel combination, for this reason selection of patients 
for either treatment must consider the differences between both phase 3 pivotal 
trials. The phase 2 trial LAPACT also provide us some information for unresect-
able patients that underwent gemcitabine- nab paclitaxel treatment looking for a 
neoadjuvant option considering that phase 3 trial MPACT only enrolled metastatic 
patients. MPACT trial allowed the inclusion of patients older than 75 years (10%) 
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and poorer performance status (8% ECOG 2), in the FOLFIRINOX phase 3 trial 
patients older than 75 years were not allowed and ECOG was limited to <2. Despite 
that FOLFIRINOX trial was a multicenter only included French sites, however, 
MPACT included patients from North America, Europe, and Australia.
A systematic meta-analysis aimed to answer if there is superiority of 
FOLFIRINOX or gemcitabine-nab paclitaxel combination in the first line of treat-
ment for metastatic or advanced PC. Based on 16 retrospective studies that included 
2123 gemcitabine plus nab-paclitaxel treated patients and 1690 FOLFIRINOX 
treated patients, no statistical significantly differences were found in terms of 
overall risk of death, PFS and RR. Toxicity was in line of the pivotal trials [36]. 
These results may help to conclude that despite of the numerically superiority in OS 
of the phase 3 FOLFIRINOX trial when it is compared with MPACT trial, and in the 
absence of a comparative head to head phase 3 trial for these 2 regimens, clinicians 
may use any of those according with their experience but also taking account of the 
medical conditions and biography of each patient to be treated.
BRCA 1–2 mutations have been found between the 5% and 12.8% of pancre-
atic cancer patients among different patient populations [6]. In a retrospective 
observational study that analyzed the outcomes in 71 PC patients harboring BRCA 
1–2 germline mutations, OS was statistically higher among stage 3–4 patients that 
were treated with platinum-based chemotherapy when compared with patients 
that did not use platin compounds as part of their treatment (22 versus 9 months, 
p = 0.039) [37].
Recently published, the POLO study (Pancreas Cancer Olaparib Ongoing) was 
a phase 3 multicenter doble blinded in patients with metastatic PC and BRCA1–2 
germline mutations that had received at least 16 weeks of a platinum-based pal-
liative chemotherapy and had no disease progression during the treatment, then 
patients were assigned to receive olaparib (300 mg twice daily) or placebo in a 2:1 
ratio [38]. The primary end point of the trial was PFS by a blinded independent 
central review. 154 patients were randomized (3315 patients screened). 86% of the 
olaparib group and 81% of the placebo group had been treated with FOLFIRINOX 
regimen and 2 and 5% with gemcitabine cisplatin combination, respectively. 
Primary end point, PFS was met showing longer median PFS among patients 
treated with olaparib versus placebo (7.4 versus 3.8 months, HR 0.53, p = 0.004), 
however, no benefit in overall survival was found for 18.9 months in olaparib 
arm and 18.1 months in placebo arm (p = 0.68). 23% of patients olaparib-treated 
had response (including 2 patients that achieved a complete response) vs. 12% in 
the placebo arm by blinded independent central review, with a median duration 
of response of 24.9 versus 3.7 months respectively. Considering that POLO trial 
resulted in a positive trial achieving to meet its primary end point PFS, FDA in 
December 2019 got the approval for the use of olaparib for the maintenance treat-
ment of adult patients with germline BRCA-mutated metastatic adenocarcinoma 
of the pancreas without disease progression on at least 16 weeks of a first-line 
platinum-based chemotherapy regimen such as FOLFIRINOX and cisplatin-based 
chemotherapy. This way, olaparib became the first drug to be approved as a main-
tenance treatment for pancreatic cancer and currently is a new weapon to improve 
PFS among BRCA-mutated PC patients.
5.  Second-line systemic therapy for metastatic or local advanced 
unresectable adenocarcinoma of the pancreas
After progression to a first-line therapy, subsequent treatment will depend 
greatly on the patient performance status and which drugs were or not given before. 
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Other factors to take in account are molecular abnormalities like dMMR/MSI-H or 
mutations that can be targeted (druggable mutations).
Patient that received gemcitabine-based chemotherapy as the first-line therapy 
can be treated with a combination of 5-FU and nanoliposomal irinotecan (nal-IRI). 
The phase III Napoli-1 trial showed an overall survival difference of 1.9 months (6.1 
versus 4.2) when compared with 5-fluorouracil monotherapy (HR 0.67) [39]. 45% 
of the patients had received 5-FU treatment as a previous line, but only 10% of the 
patients had received irinotecan previously. A subgroup analysis showed that the 
benefit was maintained in patients that had received 5-FU but not in those previ-
ously treated with irinotecan. A recent update of this trial showed an estimated 
1-year survival of 26% for nanoliposomal irinotecan plus 5-FU combination versus 
16% for 5 FU alone [40].
Nanoliposomal irinotecan is not yet widely available. Phase two trials have 
shown than irinotecan plus 5-fluorouracil and leucovorin (FOLFIRI) has modest 
activity, but comparable to nal-Iri, in patients previously treated with gemcitabine, 
with an overall response rate of 15% and 35% of stable disease, time to progression 
3.7 months and median OS of 6 months [41, 42]. The 2018 American Society of 
Clinical Oncology (ASCO) guidelines for treatment of metastatic PC endorses the 
use of FOLFIRI in countries were nal-Iri is not available [43].
Oxaliplatin-containing regimens such as FOLFOX or oxaliplatin plus 5-FU have 
yielded mixed results as a second line in this setting, with poor accrual and modest 
benefit. The multicenter German phase III Conko-003 trial compared OFF regi-
men (oxaliplatin, folinic acid and fluorouracil) against fluorouracil and folinic acid 
(FF) in patients that had disease progression after gemcitabine treatment. This trial 
resulted positive in terms of overall survival (median overall survival 5.9 months 
for OFF regimen and 3.3 months for FF regimen, HR 0.66 p = 0.01) and in terms 
of time to progression (2.9 months for OFF and 2.0 months for FF respectively, HR 
0.68, p = 0.19). Reported neurotoxicity grade 1–2 was higher among OFF- treated 
patients (38% versus 7% in FF group) [44]. Conversely, the phase III PANCREOX 
trial failed to show benefit for FOLFOX as second line therapy as compared to 5FU 
single therapy [45]. With those results, oxaliplatin based regimens are less preferred 
than nal-Iri or irinotecan-based regimens, but still an option in patients who cannot 
receive the latter for any circumstances and are still fit and willing to pursue further 
therapy.
When the combination of irinotecan, oxaliplatin, leucovorin and 5FU 
(FOLFIRINOX) regimen is given as a first line therapy, patient in good shape could 
be treated with a gemcitabine-based regimen. Reports have shown feasibility of this 
regimen [46, 47], but there are no phase III trials supporting this recommendation. 
As a result, from first line chemotherapy toxicity and declined performance status, 
it is advisable to use an attenuated regimen in this situation, reducing doses or 
changing schedules to biweekly administration [48].
Patients with poor performance status, but still fit enough and willing to receive 
further therapy, should not receive multiagent regimens. Gemcitabine or 5-FU 
single drug could represent an option for those patients, given the toxicities associ-
ated with more intense regimens and modest benefit.
An analysis that included 1503 patients from 34 trials for the second line of 
treatment for pancreatic cancer showed a median overall survival of 6 months 
among treated patients and 2.8 months for patients that underwent best supportive 
care but no chemotherapy (p = 0.013). Patients treated with either gemcitabine or 
platinum-based chemotherapy showed better outcomes when compared with other 
regimens, reported progression free survival was 4 months versus 1.6 months  
(p 0.059) and reported median overall survival was 6 months versus 5.3 months  
(p = 0.1), respectively [49].
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Immunotherapy may represent an option in a very selected group of patients. 
A phase II trial showed promising activity of pembrolizumab, a PD-1 blocking 
antibody, in gastrointestinal cancers with deficiency of mismatch repair (dMMR) or 
high microsatellite instability (MSI-H) [50]. These finding lead to the site agnostic 
FDA approval for checkpoint inhibitors for dMMR/MSI-H tumors. ASCO 2018 
guidelines for metastatic pancreatic cancer recommends dMMR/MSI-H testing to 
all patients with metastatic PC seeking for second line therapy, although this has 
modest real impact in PC, given that those abnormalities are present in only percent 
less than one percent of the patients [7].
Multiple gene testing with next generation sequencing test can lead to the identi-
fication of potentially target therapy that can be helpful for patients with metastatic 
PC, but there is no trial showing clear benefit of using this strategy. There are 
ongoing randomize trials exploring these options, making it a better option when 
available.
Stromal-depleting agents such as PEGPH20 have shown promising results in a 
phase 2 trial in untreated patients when combining with gemcitabine-Nab-pacli-
taxel in high hyaluronic acid population. These results have not been reproduced 
when PEGPH20 has been combined with FOLFIRINOX [51].
6. Conclusions
Pancreatic cancer is one of the most lethal malignancies among solid tumors 
and unfortunately most of the times it is diagnosed as a metastatic or unresectable 
disease with null chances of cure.
First systemic treatments for advanced pancreatic carcinoma were controversial 
in results and poor outcomes were historically reported.
In the 90’s decade gemcitabine became the standard of care for advanced 
disease, with a mild improve in survival and in response rates. Looking to improve 
survival, response rate and quality of life several gemcitabine-based chemotherapy 
combinations were assessed in clinical trials but most of them failed in their pri-
mary end points. Despite, gemcitabine- erlotinib combination resulted in a positive 
trial in statistical terms when compared with gemcitabine alone, allowing to get 
FDA approval, the clinical significance was poor and currently it is not a recom-
mended treatment as a first option.
No relevant advances were reported until 2011 when a phase 3 French clinical 
trial in advanced PC showed that FOLFIRINOX when compared with gemcitabine 
improved OS and response rate in advanced PC but with higher toxicity. 2 years 
later, in 2013, the publication of another phase clinical trial showed that gem-
citabine plus nab-paclitaxel combination was superior than gemcitabine in terms 
of survival and responses, including patients older than 75 years and with worse 
performance status (0–2) than the French trial (0–1). Nevertheless, no phase 3 
clinical trials have been conducted in order to answer which treatment is better than 
the other. Meta-analysis that have included both treatments show that apparently 
both regimens are similar in efficacy.
A recent publication showed that among BRCA-mutated advanced-PC adding 
olaparib as a maintenance treatment, in patients without disease progression after 
FOLFIRINOX, improves progression free survival but until now no benefit in 
overall survival has been reported.
Second-line therapy will depend on previous therapy and current performance 
status. Options for patients treated with gemcitabine-based regimens are 5-fluo-
rouracil plus leucovorin plus either nanoliposomal irinotecan, irinotecan or oxali-
platin. Patients that were treated with first line FOLFIRINOX may benefit from a 
Pancreatic Cancer
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gemcitabine-based chemotherapy, but evidence from randomized trials is lacking. 
Other options like immunotherapy and targeted therapies yield benefit only in very 
selected cases, and it is still an area of research.
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